Heuristik Takes Its Technology to Taiwan After Securing €750,000

Heuristik launches in Asia. The Spanish biometrics company for the health sector will implement its patient identification and management technology combining fingerprinting with artificial intelligence (AI) in Taiwan. Heuristik will carry out a pilot test in hospitals throughout the country, according to Antxon Caballero, the company’s CEO.

The company has a financing round open with which it expects to attract €1.3 million. At the moment, €750,000 have been secured by Spanish and European investors, an amount that could be closed in the coming months.

With the investment, the group plans to continue increasing its international expansion. In 2023, the company increased its presence in Spain and confirmed its arrival in Portugal and Poland. Now, Heuristik takes the first step to expand across the Asian continent, while also continuing to look at the United States. 

The landing in Taiwan comes after being selected by the accelerator BeAccelerator, which has $150 million to invest in its portfolio of companies. Heuristik has been the only Spanish company in the entity’s selection.

Read more details about Heuristik and find the most important financial news of the day with our companion app Born2Invest.

Heuristik has been selected by BeAccelerator

Throughout 2023-2024, Heuristik has the objective of opening a financing round of €5 million, which will allow the Spanish company to continue growing in the European market and complete the necessary requirements to enter the US market. The company has already held talks with a Boston hospital, whose name has not been released, to test its pilot there, and plans to enter the country in 2024.

The start-up has developed software that combines fingerprint recognition with artificial intelligence. This solution helps health entities with the identification of patients throughout the patient journey, providing real-time statistics that help lighten waiting lists.

With this tool, the company intends to speed up the identification of patients in situations of medical emergencies, post-operatives, and health centers. This encompasses any situation where users are unconscious, without documentation, or suffer from a communication problem, such as Alzheimer’s or deafness.

The company aims to open a financing round of €5 million between 2023 and 2024

In the last month, the company has also completed a new pilot project at the San Cecilio Hospital in Granada, with the aim of applying its technology to dialysis in chronic patients at the hospital and day centers.

The group is now closing some thirty tests distributed in Europe, Asia, and America. Likewise, it is preparing to opt for the EIC Accelerator at the end of the year and thus achieve implementation of its solution in six European countries. Recently, the company obtained the Vithas award, which is supported by the accelerator Acex Healthcare.

Currently, Heuristik, based in Bilbao, has sixteen workers spread across different cities in Spain, including Barcelona, ​​Galicia, Malaga, Madrid, Valladolid, and Bilbao.

__

(Featured image by  ar130405 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.